Fry Laboratories
This site requires the Flash 7 plug-in. If you're seeing this text, you probably don't have it. Click here to get the Flash plug-in.
Fry Laboratories
In addition to being the Founder, Director, and Principal Investigator of our laboratory, Stephen E. Fry, M.S., M.D., is an active General Practitioner in Scottsdale. Dr. Fry first became interested in autoimmune diseases 10 years ago after seeing the debilitative effects that these diseases can have on patients. Dr. Fry's busy clinical practice, as well as his interest in analyzing the causative agents of autoimmune disease have led to the development of our lab. A large portion of Dr. Fry's patients include those who suffer from chornic fatigue, fibromyalgia, lyme disease, and other complicated autoimmune diseases. Dr. Fry is a member of I.L.A.D.S., the Arizona Biotechnology Consortium, and he holds many patents on cutting edge biotechnological and diagnostic innovations.
University of Arizona 1975 B.S. - Microbiology
University of Arizona 1978 M.S. - Molecular Biology
Sara Oliver Springer 1979 Scholarship - Cancer Research
University of Arizona 1990 M.D. - Medicine
Good Samaratin Regional 1991 PGY-1 - Internship
St. Joseph's Hospital 1992 PGY-2 - Surgial Pathology
1. Buick, R.N., Fry, S.E., Salmon, S.E., and Stanisic, T.H. (1979). A colony assay for progenitor cells from transitional cell carcinoma of the bladder. AACR abstract 15th Annual AACR, New Orleans, 1979.
2. Fry, S.E. (1979). Stimulation of recombination in phage T4 by nitrous-acid-induced lesions. J. Gen. Virol. 43: 719-22.
3. Stanisic, T.H., Buick, R.N., Trent, J.M., and Fry, S.E. (1980). In vitro clonal assay for bladder cancer: studies of the biologic potential of the urothelium and determination of in vitro sensitivity to cytotoxic agents. Surg. Forum vol. XVIII, p580.
4. Stanisic, T.H., Buick, R.N., Trent, J.M., Fry, S.E., and Salmon, S.E. (1981). An in vitro colonal assay for bladder cancer: studies of the biologic potential of the urothelium and determination of in vitro sensitivity to cytotoxic agents. J. of Surg. Urology 18: 67-72.
5. Ellis, J.E., Prochazka, M., and Fry, S.E. (2009). In Situ Hematologic Biofilm Community in 3 Patients with Amyotrophic Lateral Sclerosis. 5th ASM Conference On Biofilms, A115.